April 4, 2016 Precision medicine brings new hope to those with advanced urothelial cancer Five of six patients with advanced
metastatic urothelial cancer and at least one of two specific genetic abnormalities, responded to treatment with afatinib, which was approved in 2013 by the Food and Drug Administration for patients with lung cancer, researchers report online in the Journal of Clinical Oncology.
The designation is specifically for patients with locally advanced or
metastatic urothelial cancer who have previously been treated with immune checkpoint inhibitors.
A Randomized, Double - Blinded, Phase II Study of Maintenance Pembrolizumab versus Placebo after First - line Chemotherapy in Patients with
Metastatic Urothelial Cancer
Not exact matches
Participants have been asked to take part in this research study because they have
metastatic or surgically unresectable
urothelial cancer with FGF / FGFR alterations.